The Journal of Allergy and Clinical Immunology
Volume 118, Issue 6 , Pages 1369-1374 , December 2006

Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy

  • Mike P. Williamson, PhD, DSc

      Affiliations

    • From the Department of Molecular Biology and Biotechnology, University of Sheffield
    • ,
  • Theron G. McCormick, MD

      Affiliations

    • Section of Allergy and Immunology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital
    • ,
  • Christina L. Nance, PhD

      Affiliations

    • Section of Allergy and Immunology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital
    • Corresponding Author InformationReprint requests: Christina L. Nance, PhD, Department of Allergy and Immunology, Texas Children's Hospital, 6621 Fannin, MC: FC330.01, Houston, TX 77030.
    • ,
  • William T. Shearer, MD, PhD

      Affiliations

    • Section of Allergy and Immunology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital

Received 11 October 2005 ,Revised 11 August 2006 ,Accepted 16 August 2006.

References 

  1. Janeway CA, Carding S, Jones B, Murray J, Portoles P, Rasmussen R, et al. CD4+ T cells: specificity and function. Immunol Rev. 1988;101:39–80
  2. D'Souza MP, Cairns JS, Plaeger SF. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA. 2000;284:215–222
  3. NCI . Clinical development plan: tea extracts: green tea polyphenols: epigallocatechin gallate. J Cell Biochem. 1996;26:236–257
  4. Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 2002;53:19–34
  5. Fassina G, Buffa A, Benelli R, Varnier OE, Noonan DM, Albini A. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS. 2002;16:939–941
  6. Deana R, Turetta L, Donella-Deana A, Dona M, Brunati AM, De Michiel L, et al. Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists. Thromb Haemost. 2003;89:866–874
  7. Ludwig A, Lorenz M, Grimbo N, Steinle F, Meiners S, Bartsch C, et al. The tea flavonoid, epigallocatechin-3-gallate, reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun. 2004;316:659–665
  8. Jöbstl E, O'Connell J, Fairclough JP, Williamson MP. Molecular model for astringency produced by polyphenol/protein interactions. Biomacromolecules. 2004;5:942–949
  9. Sakata R, Ueno T, Nakamura T, Sakamoto M, Torimura T, Sata M. Green tea polyphenol, epigallocatechin-3-gallate, inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol. 2004;40:52–59
  10. Charlton AJ, Haslam E, Williamson MP. Multiple conformations of the proline-rich protein/epigallocatechin gallate complex determined by time-averaged nuclear Overhauser effects. J Am Chem Soc. 2002;124:9899–9905
  11. Wang YC, Bachrach U. The specific anti-cancer activity of green tea (-)-epigallocatechin-3-gallate (EGCG). Amino Acids. 2002;22:131–143
  12. Nakane H, Ono K. Differential inhibition of HIV-reverse transcriptase and various DNA and RNA polymerases by some catechin derivatives. Nucleic Acids Symp Ser. 1989;21:115–116
  13. Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, et al. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol. 2003;112:951–957
  14. Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath AK, et al. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta. 2005;1723:270–281
  15. Nance C, Williamson M, McCormick T, Shearer W. Binding of the green tea polyphenol, epigallocatechin gallate, to the CD4 receptor on human CD4+T cells resulting in inhibition of HIV-1-gp120 binding. Clin Immunol. 2005;115:S245
  16. Jacobson J, Israel R, Lowy I, Ostrow N, Vassilatos L, Barish M, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004;48:423–429
  17. Machius M. Structural biology: a high-tech tool for biomedical research. Curr Opin Nephrol Hypertens. 2003;12:431–438
  18. Charlton AJ, Baxter NJ, Khan ML, Moir AJ, Haslam E, Davies AP, et al. Polyphenol/peptide binding and precipitation. J Agric Food Chem. 2002;50:1593–1601
  19. Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc. 2001;123:6108–6117
  20. Benie AJ, Moser R, Bauml E, Blaas D, Peters T. Virus-ligand interactions: identification and characterization of ligand binding by NMR spectroscopy. J Am Chem Soc. 2003;125:14–15
  21. Meyer B, Peters T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem Int Ed Engl. 2003;42:864–890
  22. Wu H, Myszka DG, Tendian SW, Brouillette CG, Sweet RW, Chaiken IM, et al. Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Proc Natl Acad Sci U S A. 1996;93:15030–15035
  23. Arthos J, Deen KC, Chaikin MA, Fornwald JA, Sathe G, Sattentau QJ, et al. Identification of the residues in human CD4 critical for the binding of HIV. Cell. 1989;57:469–481
  24. Nance CL, Shearer WT. Is green tea good for HIV-1 infection?. J Allergy Clin Immunol. 2003;112:851–853
  25. Hamza A, Zhan CG. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? mechanistic insights from computer modeling and the implication for rational design of anti-HIV-1 entry inhibitors. J Phys Chem B. 2006;110:2910–2917
  26. Lee M, Wang Z, Li H, Chen L, Sun Y, Gobbo S, et al. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev. 1995;4:393–399
  27. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, et al. Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A. 2000;97:9026–9031
  28. Patterson LJ, Aberdeen A, Kone J, Haben M, Raymond M, Berkower I. Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4. Biochem Biophys Res Commun. 2001;285:639–643
  29. Gelderblom HR, Hausmann EH, Ozel M, Pauli G, Koch MA. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology. 1987;156:171–176
  30. Zhu P, Chertova E, Bess J, Lifson JD, Arthur LO, Liu J, et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A. 2003;100:15812–15817
  31. Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev. 2002;11:1025–1032
  32. Behr M, Small P. Inhibition of carcinogenesis by tea. Nature. 1997;389:134–135
  33. Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. J Nutr. 2003;133:3262S–3267S
  34. Lipton SA. Turning down, but not off. Nature. 2004;428:473
  35. Beliveau R, Gingras D. Green tea: prevention and treatment of cancer by nutraceuticals. Lancet. 2004;364:1021–1022
  36. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors. 2000;13:49–54

 Supported by National Institutes of Health grants AI27551, AI36211, HD41983, RR0188, HL079533, HL72705, and RAT003084A and contract AI41089; the Pediatric Research and Education Fund, Baylor College of Medicine; and the David Fund, Pediatrics AIDS Fund, and Immunology Research Fund, Texas Children's Hospital.Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(06)01763-5

doi: 10.1016/j.jaci.2006.08.016

The Journal of Allergy and Clinical Immunology
Volume 118, Issue 6 , Pages 1369-1374 , December 2006

Article Tools

* Image Usage & Resolution